Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy.

JCO Precis Oncol · 2026 · PMC13048326 · PMID 41911515

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In contrast, PIK3CA mutations (13.4%, 42/313) and co-occurrence of both mutations and amplifications (n = 13) showed a trend toward shorter OS compared with wild type, but without statistical significance (HR, 1.43 [95% CI, 0.94 to 2.17]; P = .17 and HR, 1.94 [95% CI, 0.85 to 4.45]; P = .10, respectively; Fig 3 C).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.